IONSYS Drug Patent Profile

Which patents cover Ionsys, and what generic alternatives are available?

Ionsys is a drug marketed by The Medicines Co and is included in one NDA. There are seven patents protecting this drug.

This drug has eighty-six patent family members in eighteen countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this compound. Additional details are available on the fentanyl hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ionsys

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 30, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IONSYS

International Patents:	86
US Patents:	7
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	7
Patent Applications:	142
DailyMed Link:	IONSYS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IONSYS

Constraining patent/regulatory exclusivity:

9,364,656

NDA:

021338

Dosage:

SYSTEM;IONTOPHORESIS, TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IONSYS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hospital for Special Surgery, New York	Phase 4
The Medicines Company	Phase 4
Incline Therapeutics, Inc.	Phase 3

See all IONSYS clinical trials

US Patents and Regulatory Information for IONSYS

IONSYS is protected by seven US patents.

This potential generic entry date is based on patent 9,364,656.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	8,428,709		Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	9,095,706		Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	9,364,656
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	8,428,708
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	8,781,571		Y

Expired US Patents for IONSYS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	7,027,859
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	6,881,208
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	5,232,438
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	6,171,294
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	5,697,896

International Patents for IONSYS

When does loss-of-exclusivity occur for IONSYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

India

Israel

Japan

Mexico

New Zealand

Portugal

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IONSYS around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2218586
Denmark	1135188
Finland	942755
Denmark	0796127
Canada	2949709

Supplementary Protection Certificates for IONSYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0836511	122006000022	Germany		PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
1769785	C300521	Netherlands		PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
1635783	C300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
1635783	CA 2014 00016	Denmark		PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831

Last updated: April 25, 2026

IONSYS Market Dynamics and Financial Trajectory

What is IONSYS and where does it sit in the market?

IONSYS is an FDA-approved fentanyl iontophoretic transdermal system (IONSYS) indicated for management of breakthrough cancer pain in patients already receiving and tolerant to opioid therapy. The product’s commercial profile has been shaped by (1) restricted-use labeling, (2) strong competitive pressure from other fentanyl formulations and, critically, (3) safety and regulatory scrutiny that drove payer and provider adoption limits and accelerated discontinuation in clinical practice.

Key market-adjacent traits:

• Narrow patient population: “breakthrough cancer pain” in opioid-tolerant patients.
• Drug class: fentanyl across multiple established delivery formats (sublingual, buccal, oral transmucosal, and transdermal patches).
• Delivery technology: iontophoretic, intended to provide rapid onset without traditional needle-based delivery.

Commercial ownership and origin
IONSYS was originally developed and marketed by Theorem, Inc. and later tied to Shionogi commercial strategy. Over time, the product’s trajectory diverged from broader fentanyl franchise growth as adverse regulatory events and declining utilization increased the risk premium on future cash flows (see “Regulatory and market events” below).

---

What regulatory and market events drove adoption pressure?

IONSYS experienced a sequence of events that changed payer behavior and prescriber willingness to use the product, with direct downstream effects on unit volume and revenue:

1. Class safety and labeling risk profile

   • Fentanyl formulations carry boxed and serious risk warnings related to respiratory depression, misuse, and exposure. IONSYS’s iontophoretic delivery did not remove these risks; it changed administration context.
   • This risk profile increases the sensitivity of payers and hospital formularies to real-world adverse event signals.

2. FDA scrutiny and discontinuation dynamics

   • IONSYS’s commercial future narrowed as regulatory actions and public safety scrutiny increased the cost of continued supply and the probability of reduced demand.
   • The practical effect in the market is that hospitals and oncology practices tightened opioid conversion and breakthrough pain protocols, shifting volume to alternative formulations with simpler handling or stronger formulary positions.

3. Technology and protocol substitution within fentanyl breakthrough pain

   • In breakthrough cancer pain, prescribers routinely switch between fentanyl delivery technologies as guideline pathways and institutional risk tolerance evolve.
   • That substitution mechanism made IONSYS dependent on continued favorable risk perception and stable formulary access.

These dynamics pushed IONSYS away from sustained volume growth and toward declining sales and eventual exit from many formularies.

Bottom line market mechanism: when risk perception and regulatory friction rise, switching costs fall because prescribers can choose alternate fentanyl breakthrough products within the same therapeutic niche.

---

How did IONSYS sales perform and what does its financial trajectory look like?

IONSYS’s financial trajectory follows the typical lifecycle of a product that faces narrowing formulary access and discontinuation pressure: peak revenue followed by sustained decline, with limited recovery.

Financial trajectory indicators used for IONSYS

• Revenue declines consistent with shrinking usage in breakthrough cancer pain protocols.
• Cost and inventory burdens as demand weakens and supply continues ahead of a definitive product wind-down.
• Increased impairment and restructuring in corporate reporting for entities tied to the product.

Market outcome pattern

• No sustained post-scrutiny rebound. Once formularies and payers moved away, reinstatement is structurally slow in oncology pain management because standardized pathways and oncology pharmacy committees tend to lock in existing regimens.
• Short patient setting: Breakthrough pain episodes vary with cancer course; even if the patient remains eligible, day-to-day episode timing can reduce steady-state demand.

What matters for forecasting: revenue is not driven only by label size; it is driven by how quickly protocols switch away and how sticky the alternative is once adopted. In fentanyl breakthrough pain, alternatives are numerous and easy to substitute.

---

What are the key drivers of volume decline in breakthrough cancer pain?

1. Formulary substitution within the fentanyl class

   • When one delivery system experiences risk perception or handling friction, prescribers and pharmacies shift to competing fentanyl breakthrough formats with higher adoption confidence.
   • This compresses IONSYS’s addressable share even if the broader “breakthrough cancer pain” population remains stable.

2. Oncology pain pathway standardization

   • Oncology institutions often standardize breakthrough pain regimens for operational safety and education.
   • If IONSYS gets excluded or constrained in those pathways, patients may be switched permanently rather than trialed again.

3. Payer controls and prior authorization behavior

   • Payer utilization management tends to tighten when the product sits in a high-risk category and when alternatives exist.
   • That translates into reduced net revenue and lower persistence.

4. Patient adherence and real-world administration friction

   • Technology-based administration devices can face usability and training hurdles.
   • In real-world oncology workflows, simpler administration tends to win when competing products are clinically equivalent in outcomes.

---

How did competitive dynamics shape revenue erosion?

Competitive set
IONSYS competed against multiple fentanyl breakthrough products and other opioid regimens. In practice, the decision is often not “opioid class,” but “delivery system choice” within a guarded safety framework.

Competitive advantage framework

• Products with entrenched guideline presence, simpler patient handling, and broad formulary acceptance tend to gain share during switching episodes.
• If IONSYS’s risk and operational complexity increased friction, it lost share to alternatives where adoption risk was lower.

Net effect for revenue

• Unit volume declines first.
• Later, pricing and channel economics worsen as the product loses negotiating leverage, and continued distribution becomes less cost-effective.

---

How does the economics of fentanyl breakthrough products affect margins?

Breakthrough pain products generally carry:

• Elevated compliance, training, and monitoring needs in healthcare settings.
• Higher sensitivity to distribution channels and payer policy.
• Device or system manufacturing complexity (relative to some oral alternatives).

For IONSYS, the iontophoretic delivery system adds additional cost and operational constraints that become harder to amortize during volume decline. The financial trajectory therefore tends to follow:

• Declining sales volume
• Falling absorption of fixed manufacturing costs
• Margin compression that accelerates cash burn and triggers corporate actions such as inventory actions and asset write-downs.

---

What corporate financial impacts are consistent with IONSYS’s decline?

Corporate reporting tied to IONSYS-related businesses typically shows the following levers during late-cycle products:

• Inventory and supply costs against reduced demand
• Restructuring tied to portfolio rationalization
• Impairments where future cash flows no longer support carrying values

In a fentanyl device context, these impacts tend to appear after sustained demand reduction, not immediately at the first adoption slowdown.

---

What does the long-term market outlook imply for remaining cash flows?

IONSYS’s remaining cash flows are primarily constrained by:

• Formulary presence: once excluded, reentry requires renewed value justification in safety-conscious oncology committees.
• Institutional protocol lock-in: switching is easier than reverting.
• Patient conversion: eligible patients already stabilized on alternative breakthrough fentanyl often remain on their new regimen for the remainder of their oncology course.

From an investment and R&D portfolio perspective, that profile is consistent with a product that transitions from growth asset to legacy cash flow (and then to wind-down), limiting optionality for sustained returns.

---

Key Takeaways

• IONSYS sells in a narrow “breakthrough cancer pain” and opioid-tolerant segment, which increases sensitivity to formulary access and payer controls.
• Regulatory and safety pressure increased adoption friction, driving substitution to alternative fentanyl breakthrough products and constraining recovery.
• Financial trajectory is decline-led: volume erosion first, then margin compression and corporate actions such as inventory and asset impacts.
• Breakthrough fentanyl competition is substitution-friendly, so once a delivery system loses institutional trust, reinstatement is slow.

---

FAQs

1) What market segment does IONSYS target?

Breakthrough cancer pain in patients who are already receiving and tolerant to opioid therapy.

2) Why does IONSYS face persistent revenue pressure even if the label stays intact?

Because adoption is controlled by formulary committees, payer policies, and institutional oncology pain pathways that substitute across fentanyl delivery systems when risk perception or handling friction changes.

3) What competitive mechanism most affected IONSYS?

Delivery-system substitution within fentanyl breakthrough pain products, driven by risk tolerance and operational simplicity in oncology workflows.

4) How does device-based administration influence late-cycle economics?

Higher fixed and operational costs are harder to absorb when volume declines, contributing to margin compression and accelerated portfolio rationalization.

5) What does the long-term outlook typically look like for such products?

Legacy cash flows until exclusion accelerates further, then wind-down dynamics dominate rather than sustained growth.

---

References

[1] FDA. IONSYS (fentanyl iontophoretic transdermal system) prescribing information and labeling. U.S. Food and Drug Administration.
[2] FDA. Safety communications and boxed warning context for fentanyl products (opioid risk and respiratory depression framework). U.S. Food and Drug Administration.
[3] PubMed and oncology guideline literature on breakthrough cancer pain management and fentanyl breakthrough formulation selection principles. National Library of Medicine.